114 related articles for article (PubMed ID: 20673499)
81. Overexpression and gender-specific differences of SRC-3 (SRC-3/AIB1) immunoreactivity in human non-small cell lung cancer: an in vivo study.
Wang H; Zhang D; Wu W; Zhang J; Guo D; Wang Q; Jing T; Xu C; Bian X; Yang K
J Histochem Cytochem; 2010 Dec; 58(12):1121-7. PubMed ID: 20852035
[TBL] [Abstract][Full Text] [Related]
82. Correction to: Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1.
Deng Y; Ma G; Vallega KA; Wang D; Wang M; Wang C; Wang S; Ramalingam SS; Sun SY
Cancer Gene Ther; 2022 Nov; 29(11):1801-1802. PubMed ID: 35538225
[No Abstract] [Full Text] [Related]
83. Novel Pyrimidinones as SHP2 Antagonists for Treating Cancer.
Sabnis RW
ACS Med Chem Lett; 2021 Jan; 12(1):3-4. PubMed ID: 33488954
[No Abstract] [Full Text] [Related]
84. The prognostic significance of SHP2 and its binding protein Hook1 in non-small cell lung cancer.
He L; Li Y; Huang X; Cheng H; Ke Y; Wang L
Onco Targets Ther; 2019; 12():5897-5906. PubMed ID: 31413587
[TBL] [Abstract][Full Text] [Related]
85. Functions of Shp2 in cancer.
Zhang J; Zhang F; Niu R
J Cell Mol Med; 2015 Sep; 19(9):2075-83. PubMed ID: 26088100
[TBL] [Abstract][Full Text] [Related]
86. The expression of hypoxia-inducible factor-1α and its clinical significance in lung cancer: a systematic review and meta-analysis.
Ren W; Mi D; Yang K; Cao N; Tian J; Li Z; Ma B
Swiss Med Wkly; 2013; 143():w13855. PubMed ID: 24018850
[TBL] [Abstract][Full Text] [Related]
87. [Expression and its clinical significance of SHP2 in non-small cell lung cancer].
Tang C; Zhou X; Yang H; Wang Q; Zhang R
Zhongguo Fei Ai Za Zhi; 2010 Feb; 13(2):98-101. PubMed ID: 20673499
[TBL] [Abstract][Full Text] [Related]
88. Expression of SHP2 and related markers in non-small cell lung cancer: a tissue microarray study of 80 cases.
Tang C; Luo D; Yang H; Wang Q; Zhang R; Liu G; Zhou X
Appl Immunohistochem Mol Morphol; 2013 Oct; 21(5):386-94. PubMed ID: 23343958
[TBL] [Abstract][Full Text] [Related]
89. [Expression and clinical significance of SHP2 in the tumor tissues of smokers with lung cancer].
Zhan X; Dong H; Sun C; Liu L; Wang D; Wei Z
Zhongguo Fei Ai Za Zhi; 2010 Sep; 13(9):877-81. PubMed ID: 20840817
[TBL] [Abstract][Full Text] [Related]
90. [Clinicopathological and prognostic significance of ERα and ERβ expression in lung carcinomas: a tissue microarray study].
Yang X; Xue LY; Liu Y; Guo L; Wen P; Lin DM
Zhonghua Zhong Liu Za Zhi; 2013 Sep; 35(9):678-83. PubMed ID: 24332055
[TBL] [Abstract][Full Text] [Related]
91. Prognostic significance of CD44s expression in resected non-small cell lung cancer.
Ko YH; Won HS; Jeon EK; Hong SH; Roh SY; Hong YS; Byun JH; Jung CK; Kang JH
BMC Cancer; 2011 Aug; 11():340. PubMed ID: 21819617
[TBL] [Abstract][Full Text] [Related]
92. Expression and unique functions of four nuclear factor of activated T cells isoforms in non-small cell lung cancer.
Chen ZL; Zhao SH; Wang Z; Qiu B; Li BZ; Zhou F; Tan XG; He J
Chin J Cancer; 2011 Jan; 30(1):62-8. PubMed ID: 21192845
[TBL] [Abstract][Full Text] [Related]
93. SHP2 is up-regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis.
Zhou X; Coad J; Ducatman B; Agazie YM
Histopathology; 2008 Oct; 53(4):389-402. PubMed ID: 18643929
[TBL] [Abstract][Full Text] [Related]
94. Inhibition of SHP2 leads to mesenchymal to epithelial transition in breast cancer cells.
Zhou XD; Agazie YM
Cell Death Differ; 2008 Jun; 15(6):988-96. PubMed ID: 18421299
[TBL] [Abstract][Full Text] [Related]
95.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
96.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
97.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
98.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
99.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
100.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
